State Street Corp Cin Cor Pharma, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.0 - $29.56 $0 - $13.5 Million	-457,674 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$10.75 - $29.84 $535,328 - $1.49 Million	49,798 Added 12.21%	457,674 $5.62 Million
Q3 2022 Nov 15, 2022	BUY	$19.9 - $38.94 $3.67 Million - $7.18 Million	184,496 Added 82.59%	407,876 $13.4 Million
Q2 2022 Aug 15, 2022	BUY	$13.67 - $25.74 $1.36 Million - $2.56 Million	99,371 Added 80.13%	223,380 $4.21 Million
Q1 2022 May 16, 2022	BUY	$14.13 - $28.49 $1.75 Million - $3.53 Million	124,009 New	124,009 $2.18 Million

Ticker CINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,764,300
Description
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.